Israeli Treatment Helps All Severe Covid-19 Patients in Small Preliminary Trial

RIO DE JANEIRO, BRAZIL – According to Pluristem Therapeutics Inc., an Israeli regenerative medicine group, all patients were in the ICU with Covid-19, on ventilators, and suffering from acute respiratory syndrome. After the tests, which ran for a week, all improved and survived.

The treatment in question uses placenta, and is cell-based. Four out of the seven patients showed considerable improvement in their condition, considered severe, while three others were able to be taken off ventilators.

Four of the study subjects were in the so-called risk group, with comorbidities such as cardiovascular disease and renal failure. Nevertheless, they presented satisfactory results.

The therapy uses PLX cells, which, due to their immunological properties, would help the system to regulate and reverse the effects of pneumonia.

The company will now seek permission to conduct regular clinical trials in several countries and ultimately adopt a protocol for treating the infection caused by the novel coronavirus.

Related coverage: The Unsolved Mystery: Why Is Coronavirus More Lethal to Men? · How to Preserve Mental Health During Quarantine · Pope Francis Prophesied: "Prepare for Better Times" · Psoriasis Does not Always Represent a Risk Factor for Coronavirus

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error